Characteristics of SAA, the SII and NT-proBNP levels in patients with ACI and their value in evaluating the prognosis of thrombolytic therapy

To explore the features of serum amyloid A (SAA), the systemic immune inflammation index (SII), and N-terminal B-type natriuretic peptide (NT-proBNP) among individuals suffering from acute cerebral infarction (ACI), as well as their potential significance in assessing the adverse outcomes of thrombolytic treatment. A total of 122 patients with ACI who underwent thrombolytic therapy were included in this single-center retrospective study. Patients were categorized into short-term good prognosis (n = 81) and short-term adverse outcomes (n = 41) groups on the basis of their prognosis within 6 months after the procedure. Risk factors for poor short-term prognosis after thrombolytic therapy in ACI patients were screened via regression analysis, and the predictive value of each risk factor was assessed via receiver operating characteristic (ROC) curves. Preoperative SAA, NT-proBNP, Hcy, CRP, and the SII were significantly higher in the short-term adverse outcomes group than in the good prognosis group (p < 0.05). Specifically, the adverse outcomes group had higher mean levels of SAA, NT-proBNP, and SII (p < 0.001). The combined model (SAA, NT-proBNP, and the SII) had high predictive accuracy, with an AUC of 0.957 (p < 0.05). Pretreatment SAA, SII, and NT-proBNP levels are strongly correlated with adverse short-term outcomes of ACI patients following thrombolytic therapy.